Tobacco DependenceNCT01113424
Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum
A study testing Nicotine and Nicorette® (Nicotine Gum) in people with Tobacco Dependence, run by McNeil AB at 1 site in Sweden.
Trial summary
Bioequivalence between oral nicotine replacement products and Nicorette® gum. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Tobacco Dependence
- What is being tested?
- Nicotine and Nicorette® (Nicotine Gum)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- 1 siteSweden
- Study dates
- Sep 2008to Dec 2008
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Healthy smokers, smoking at least 10 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
- Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
- A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.
Who cannot join
- Pregnancy, lactation or intended pregnancy.
- Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Bioequivalence Between Oral Nicotine Replacement Products and Nicorette® Gum - A Study in Healthy Smokers
Bioequivalence between oral nicotine replacement products and Nicorette® gum.
Read the detailed description
This study compares a new oral Nicotine Replacement Therapy (NRT) product containing 2 and 4 mg nicotine with Nicorette® gum 2 mg and 4 mg, after 12 hours of nicotine abstinence, with respect to nicotine pharmacokinetics, during 10 hours after start of administration. Single doses of each treatment are given once in the morning during four separate treatment visits scheduled in a crossover setting with randomized treatment sequences. The study will include 88 healthy smokers between 18-50 years, who have been smoking at least 10 cigarettes daily during at least one year preceding inclusion. Subjects and study personnel will be aware of which treatment is administered at a given visit.
- Conditions
- Tobacco Dependence
- Being tested
- Nicotine, Nicorette® (Nicotine Gum)
- Keywords
- Smoking Cessation, Nicotine pharmacokinetics
- Medical subject headings
- Tobacco Use Disorder, Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NicotineDrug
Also called Not yet marketed
Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
Nicorette® (Nicotine Gum)Drug
Also called Nicorette®
Single-dose of marketed nicotine gum 2 mg or 4 mg
| Study group | Role | What they receive |
|---|---|---|
| NRT-2 | Experimental | 2 mg single-dose of a new NRT product Receives: Drug: Nicotine |
| GUM-2 | Active comparator | 2 mg single-dose of a marketed nicotine gum Receives: Drug: Nicorette® (Nicotine Gum) |
| NRT-4 | Experimental | 4 mg single-dose of a new NRT product Receives: Drug: Nicotine |
| GUM-4 | Active comparator | 4 mg single-dose of marketed nicotine gum Receives: Drug: Nicorette® (Nicotine Gum) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetic measurements
Pharmacokinetic measurements including:
- the maximum observed nicotine concentration in plasma (Cmax)
- the area under the plasma concentration-vs.-time curve until the last measurable concentration (AUCt)
- the area under the plasma concentration-vs.-time curve until infinity (AUCinf)
Measured: Baseline and during 10 hours after product administration
Secondary outcomes (4)
Tmax
The time of occurrence of Cmax (tmax) following product administration
Measured: during 10 hours after start of product administration
λz
The terminal nicotine elimination rate constant (λz)
Measured: during 10 hours after start of product administration
Residual Nicotine
The amount of nicotine released from Nicorette® gum 2 and 4 mg during 30 minutes' chewing.
Measured: After 30 minutes of chewing
Dissolution Time
Actual time required for oral dissolution of new NRT products following product administration
Measured: From product administration until completely dissolved
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2010 (estimated)
- Study startSep 2008
- Primary completionNov 2008
- Study completionDec 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tobacco DependenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 88 participants (actual)
Sponsor and investigators
- Lead sponsor
- McNeil AB
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Elisabeth Kruse, PhD, Study director, McNeil AB
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01113424
- Sponsor's protocol ID
- NICTDP1071
- Other IDs
- 2008-003358-14, 2008
- Status last verified
- Jul 2012
- First submitted
- 28 Apr 2010
- Last updated
- 10 Jul 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bioequivalence Between Oral Nicotine Replacement Products and Nicorette® Gum - A Study in Healthy Smokers
- ClinicalTrials.gov ID
- NCT01113424
- Acronym / sponsor ID
- NICTDP1071
- Conditions
- Tobacco Dependence
- Keywords
- Smoking Cessation, Nicotine pharmacokinetics
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 88 participants (actual)
- Lead sponsor
- McNeil ABIndustry (pharma, biotech, devices)
- Study start
- Sep 2008
- Primary completion
- Nov 2008 (actual)
- Study completion
- Dec 2008 (actual)
- First posted
- 29 Apr 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Bioequivalence between oral nicotine replacement products and Nicorette® gum.
Detailed description
This study compares a new oral Nicotine Replacement Therapy (NRT) product containing 2 and 4 mg nicotine with Nicorette® gum 2 mg and 4 mg, after 12 hours of nicotine abstinence, with respect to nicotine pharmacokinetics, during 10 hours after start of administration. Single doses of each treatment are given once in the morning during four separate treatment visits scheduled in a crossover setting with randomized treatment sequences. The study will include 88 healthy smokers between 18-50 years, who have been smoking at least 10 cigarettes daily during at least one year preceding inclusion. Subjects and study personnel will be aware of which treatment is administered at a given visit.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| NRT-2 | Experimental | Drug: Nicotine2 mg single-dose of a new NRT product |
| GUM-2 | Active comparator | Drug: Nicorette® (Nicotine Gum)2 mg single-dose of a marketed nicotine gum |
| NRT-4 | Experimental | Drug: Nicotine4 mg single-dose of a new NRT product |
| GUM-4 | Active comparator | Drug: Nicorette® (Nicotine Gum)4 mg single-dose of marketed nicotine gum |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Healthy smokers, smoking at least 10 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
- Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
- A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.
Key exclusion criteria (2 listed)
- Pregnancy, lactation or intended pregnancy.
- Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NicotineAlso: Not yet marketedSingle-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg | Drug | NRT-2, NRT-4 |
| Nicorette® (Nicotine Gum)Also: Nicorette®Single-dose of marketed nicotine gum 2 mg or 4 mg | Drug | GUM-2, GUM-4 |
Primary outcome
Pharmacokinetic measurements
Time frame: Baseline and during 10 hours after product administration
Pharmacokinetic measurements including: * the maximum observed nicotine concentration in plasma (Cmax) * the area under the plasma concentration-vs.-time curve until the last measurable concentration (AUCt) * the area under the plasma concentration-vs.-time curve until infinity (AUCinf)
4 secondary outcomes
Tmax
Time frame: during 10 hours after start of product administration
λz
Time frame: during 10 hours after start of product administration
Residual Nicotine
Time frame: After 30 minutes of chewing
Dissolution Time
Time frame: From product administration until completely dissolved
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2012.
Related trials for Tobacco Dependence
Recruiting
Effectiveness of Volitional Help Sheets as an Adjunct to Treatment to Promote Behavior Change: A Pilot Study on Smoking
Tobacco Dependence
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Recruiting
Social Media Support Groups for Adolescent Vaping Cessation
Vaping, Vaping Cessation
Recruiting
The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments
Nicotine Dependence, Cigarettes, Nicotine Withdrawal
Recruiting
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
Drug Abuse, Nicotine Dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elisabeth Kruse, PhD study director
McNeil AB
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nicotine and Nicorette® (Nicotine Gum) in people with Tobacco Dependence, run by McNeil AB at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharmacokinetic measurements (time frame: Baseline and during 10 hours after product administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2012.